



Volume 2, Issue 3
April 2023

Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E_z - MINUTES

Drugs Added to the VA National Formulary WITHOUT Prior Authorization

- none

Drugs Added to the VA National Formulary WITH Prior Authorization

- Pertuzumab trastuzumab hyaluronidase (PHESGO)

Drugs Not Added to the VA National Formulary

- Spesolimab-sbzo (SPEVIGO) in Generalized Pustular Psoriasis
- Deucravacitinib (SOTYKTU) in Plaque Psoriasis
- Tick-borne encephalitis vaccine (TICOVAC)
- Pegcetacoplan (EMPAVELI)
- Naxitamab-gqgk (DANYELZA)

Formulary Drugs with Prior Authorization Removed

- Faricimab (VABYSBO) Injection

Drugs Removed from the VA National Formulary

- Nitrazine test strips (no longer available)

Other Announcements

- Tenapanor (IBSRELA) in Irritable Bowel Syndrome-Constipation Criteria reactivation
- Teprotumumab (TEPEZZA) CFU revised
- Thickening Agents CFU revised
- Dysphasia recommendations for medication assessment was revised
- Clinical recommendations for the use of intramuscular ketamine in the ED and UCC for the management of acute agitation were developed
- Clinical recommendations for the use of ketamine for acute pain in the Emergency Department or Urgent Care setting developed
- Gepant CFU revised (atogepant, rimegepant, ubrogepant)
- Buprenorphine SA Long-Acting Injectable CFU revised
- Buprenorphine Formulations for Pain Management RFU revised